Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
Abstract Background Despite the common use of topical ophthalmic corticosteroids in dogs, detailed reports on systemic and dermatologic adverse effects are limited. Results Nine purpose-bred research Beagles were treated with difluprednate 0.05% ophthalmic emulsion in one or both eyes 2–3 times dail...
Guardado en:
Autores principales: | Katelin Quantz, Amanda L. Anderson, Christine D. Harman, Erica L. Noland, Jacquelyn M. Del Valle, Laurence M. Occelli, Jessica B. Burn, Simon M. Petersen-Jones, Daniel K. Langlois, Chris G. Pirie, Annette D. Petersen, András M. Komáromy |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3ef3d59deba34f8196436fe5f73b6480 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
por: Palacio-Pastrana C, et al.
Publicado: (2020) -
Topical Difluprednate for Early Corneal Graft Rejection After Penetrating Keratoplasty
por: Said OM, et al.
Publicado: (2020) -
Difluprednate ophthalmic emulsion 0.05% (Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Stephen Smith, et al.
Publicado: (2010) -
Adrenocortical Carcinoma in Childhood: A Systematic Review
por: Maria Riedmeier, et al.
Publicado: (2021) -
Split-Second Unlearning: Developing a Theory of Psychophysiological Dis-ease
por: Matt Hudson, et al.
Publicado: (2021)